Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF +1.79%81 Peter Lynch Fair Value is $25.10 as of Jul. 13, 2026, which is 2924% above its 10-year median of 0.83. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $12.33 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 25 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 84% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Wuxi AppTec Co's PEG is 1. Wuxi AppTec Co's 5-Year TTM EBITDA Growth Rate is 25.
Wuxi AppTec Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $1.00. Therefore, the Peter Lynch Fair Value for today is $25.10.
As of today (2026-07-13), Wuxi AppTec Co's share price is $20.9425. Wuxi AppTec Co's Peter Lynch fair value is $25.10. Therefore, Wuxi AppTec Co's Price to Peter Lynch Fair Value Ratio for today is 0.83.
The historical rank and industry rank for Wuxi AppTec Co's Peter Lynch Fair Value or its related term are showing as below:
WUXIF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.5 Med: 0.83 Max: 4.91
Current: 0.71
During the past 12 years, the highest Price to Peter Lynch Fair Value Ratio of Wuxi AppTec Co was 4.91. The lowest was 0.50. And the median was 0.83.
WUXIF's Price-to-Peter-Lynch-Fair-Value is ranked better than 84% of 25
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.2
vs WUXIF: 0.71
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Wuxi AppTec Co (OTCPK:WUXIF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Wuxi AppTec Co's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
20.9425
/
25.10
=
0.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co Peter Lynch Fair Value Related Terms
Wuxi AppTec Co Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Peter Lynch Fair Value Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Price-to-Peter-Lynch-Fair-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Price-to-Peter-Lynch-Fair-Value falls into.
Wuxi AppTec Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $25.10 mean?
Wuxi AppTec Co (WUXIF) has a Peter Lynch Fair Value of $25.10 as of Jul. 13, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Wuxi AppTec Co and its competitors. This is 2924% above median its historical median of 0.83. Over the past decade, Wuxi AppTec Co's Peter Lynch Fair Value has ranged from 0.50 to 4.91. According to the industry distribution chart, Wuxi AppTec Co ranks #4 out of 25 companies in the Medical Diagnostics & Research industry, placing it in the top 16%.
Is Wuxi AppTec Co's Peter Lynch Fair Value too high?
Wuxi AppTec Co's current Peter Lynch Fair Value of $25.10 is 2924% above median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 4.91. The Medical Diagnostics & Research industry median Peter Lynch Fair Value is 2.20. Wuxi AppTec Co's value of $25.10 is 1040.9% above this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #4 out of 25 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Peter Lynch Fair Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #4 out of 25 companies for Peter Lynch Fair Value. This places Wuxi AppTec Co in the top 16% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 2.20. Wuxi AppTec Co's value of $25.10 is 1040.9% above this benchmark. Historically, Wuxi AppTec Co's own Peter Lynch Fair Value has ranged from 0.50 to 4.91 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 2.20, Wuxi AppTec Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Diagnostics & Research company?
The median Peter Lynch Fair Value among Medical Diagnostics & Research companies is 2.20, based on 25 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Peter Lynch Fair Value of $25.10 is 1040.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Peter Lynch Fair Value is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Peter Lynch Fair Value is $25.10, which is 2924% above median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.33, compared to a current price of $20.94 — trading 69.8% above its estimated fair value. The current Peter Lynch Fair Value is $25.10, which is 2924% above median its 10-year median of 0.83 and 1040.9% above the Medical Diagnostics & Research industry median of 2.20. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Peter Lynch Fair Value is $25.10 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $20.94 is trading 69.8% above its estimated GF Value™ of $12.33.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Peter Lynch Fair Value: $25.10 (2924% above median its 10-year median of 0.83)
GF Value™: $12.33 vs. price of $20.94 (69.8% above fair value)
Industry Position: 1040.9% above the Medical Diagnostics & Research median (#4 of 25)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
